Harnessing the benefits of PPARβ/δ agonists

Life Sciences

Volumn 93, Issue 25-26, 2013, Pages 963-967

  Mackenzie, Louise S ^a   Lione, Lisa ^a  

^a UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

Author keywords

Dose; Function; Induction and transrepression; PPAR ; Preclinical studies

Indexed keywords

3 [(4 ANILINO 2 METHOXYPHENYL)SULFAMOYL] 2 THENOIC ACID METHYL ESTER; 3 CHLORO 4 [3 (7 PROPYL 3 TRIFLUOROMETHYLBENZISOXAZOL 6 YLOXY)PROPYLTHIO]PHENYLACETIC ACID; 4 [4 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY)PROPOXY]PHENOXY]ACETIC ACID; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; [4 [2 (3 FLUORO 4 TRIFLUOROMETHYLPHENYL) 4 METHYL 5 THIAZOLYLMETHYLTHIO] 2 METHYLPHENOXY]ACETIC ACID; ATORVASTATIN; BEZAFIBRATE; DG 172; GFT 505; GSK 3787; ILOPROST; L 165061; L 796449; LIGAND; MBX 8025; NIMESULIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST; PLACEBO; TREPROSTINIL; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; CLINICAL TRIAL (TOPIC); DOSE RESPONSE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG POTENCY; ERYTHROCYTE COUNT; HEMATOCRIT; HUMAN; IN VITRO STUDY; METABOLIC DISORDER; NEOPLASM; NONHUMAN; PROTEIN FUNCTION; RECEPTOR BINDING; REVIEW; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; VASODILATATION;

DOSE; FUNCTION; INDUCTION AND TRANSREPRESSION; PPARΒ/Δ; PRECLINICAL STUDIES;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PPAR DELTA; PPAR-BETA; RODENTIA; THIAZOLES;

ANIMALIA; RODENTIA;

EID: 84889092515     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2013.10.022     Document Type: Review

References (66)

1. F.Y. Ali, S.J. Davidson, L.A. Moraes, S.L. Traves, M. Paul-Clark, and D. Bishop-Bailey Role of nuclear receptor signaling in platelets: antithrombotic effects of PPARbeta FASEB J 20 2006 326 328
2. F.Y. Ali, K. Egan, G.A. FitzGerald, B. Desvergne, W. Wahli, and D. Bishop-Bailey Role of prostacyclin versus peroxisome proliferator-activated receptor beta receptors in prostacyclin sensing by lung fibroblasts Am J Respir Cell Mol Biol 34 2006 242 246
3. F.Y. Ali, M.G. Hall, B. Desvergne, T.D. Warner, and J.A. Mitchell PPARbeta/delta agonists modulate platelet function via a mechanism involving PPAR receptors and specific association/repression of PKCalpha-brief report Arterioscler Thromb Vasc Biol 29 2009 1871 1873
4. G.D. Barish, A.R. Atkins, M. Downes, P. Olson, L.W. Chong, and M. Nelson PPARdelta regulates multiple proinflammatory pathways to suppress atherosclerosis Proc Natl Acad Sci U S A 105 2008 4271 4276
5. H.E. Bays, S. Schwartz, T. Littlejohn III, B. Kerzner, R.M. Krauss, and D.B. Karpf MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin J Clin Endocrinol Metab 96 2011 2889 2897
6. M.G. Belvisi, and J.A. Mitchell Targeting PPAR receptors in the airway for the treatment of inflammatory lung disease Br J Pharmacol 158 2009 994 1003
7. J. Berger, M.D. Leibowitz, T.W. Doebber, A. Elbrecht, B. Zhang, and G. Zhou Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects J Biol Chem. 274 1999 6718 6725
8. M.T. Bility, M.K. Devlin-Durante, N. Blazanin, A.B. Glick, J.M. Ward, and B.H. Kang Ligand activation of peroxisome proliferator-activated receptor beta/delta (PPAR beta/delta) inhibits chemically induced skin tumorigenesis Carcinogenesis 29 2008 2406 2414
9. D. Bishop-Bailey, and J. Bystrom Emerging roles of peroxisome proliferator-activated receptor-beta/delta in inflammation Pharmacol Ther 124 2009 141 150
10. C.R. Bueno Junior, L.C. Pantaleao, V.A. Voltarelli, L.H. Bozi, P.C. Brum, and M. Zatz Combined effect of AMPK/PPAR agonists and exercise training in mdx mice functional performance PLoS One 7 2012 e45699
11. A.D. Burdick, D.J. Kim, M.A. Peraza, F.J. Gonzalez, and J.M. Peters The role of peroxisome proliferator-activated receptor-beta/delta in epithelial cell growth and differentiation Cell Signal 18 2006 9 20
12. B. Cariou, Y. Zair, B. Staels, and E. Bruckert Effects of the new dual PPAR alpha/delta agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism Diabetes Care 34 2011 2008 2014
13. Y.J. Choi, B.K. Roberts, X. Wang, J.C. Geaney, S. Naim, and K. Wojnoonski Effects of the PPAR-delta agonist MBX-8025 on atherogenic dyslipidemia Atherosclerosis. 220 2012 470 476
14. J. Clark, R. Nasrallah, and R.L. Hebert The PPARdelta ligand GW501516 reduces growth but not apoptosis in mouse inner medullary collecting duct cells PPAR Res 2009 2009 706283
15. C. Dreyer, G. Krey, H. Keller, F. Givel, G. Helftenbein, and W. Wahli Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors Cell 68 1992 879 887
16. Y. Fan, Y. Wang, Z. Tang, H. Zhang, X. Qin, and Y. Zhu Suppression of pro-inflammatory adhesion molecules by PPAR-delta in human vascular endothelial cells Arterioscler Thromb Vasc Biol 28 2008 315 321
17. J.E. Foreman, A.K. Sharma, S. Amin, F.J. Gonzalez, and J.M. Peters Ligand activation of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) inhibits cell growth in a mouse mammary gland cancer cell line Cancer Lett 288 2010 219 225
18. B.M. Forman, J. Chen, and R.M. Evans Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta Proc Natl Acad Sci U S A 94 1997 4312 4317
19. C. Gaudel, and P.A. Grimaldi Metabolic functions of peroxisome proliferator-activated receptor beta/delta in skeletal muscle PPAR Res 2007 2007 86394
20. L.E. Geiger, WSD, D.J. Lewis, C. Brennan, K.C. Liu, and S.J. Newsholme Rat carcinogenicity study with GW501516, a PPAR delta agonist Toxicologist 108 2009 895
21. R.A. Gupta, J. Tan, W.F. Krause, M.W. Geraci, T.M. Willson, and S.K. Dey Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer Proc Natl Acad Sci U S A 97 2000 13275 13280
22. R.A. Gupta, D. Wang, S. Katkuri, H. Wang, S.K. Dey, and R.N. DuBois Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-delta accelerates intestinal adenoma growth Nat Med 10 2004 245 247
23. L.S. Harrington, L. Moreno, A. Reed, S.J. Wort, B. Desvergne, and C. Garland The PPARbeta/delta agonist GW0742 relaxes pulmonary vessels and limits right heart hypertrophy in rats with hypoxia-induced pulmonary hypertension PLoS One 5 2010 e9526
24. H.E. Hollingshead, M.G. Borland, A.N. Billin, T.M. Willson, F.J. Gonzalez, and J.M. Peters Ligand activation of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) and inhibition of cyclooxygenase 2 (COX2) attenuate colon carcinogenesis through independent signaling mechanisms Carcinogenesis 29 2008 169 176
25. I. Issemann, and S. Green Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators Nature 347 1990 645 650
26. A. Iwashita, Y. Muramatsu, T. Yamazaki, M. Muramoto, Y. Kita, and S. Yamazaki Neuroprotective efficacy of the peroxisome proliferator-activated receptor delta-selective agonists in vitro and in vivo J Pharmacol Exp Ther 320 2007 1087 1096
27. Y. Jeong, Y. Xie, G. Xiao, C. Behrens, L. Girard, and I. Wistuba Nuclear receptor expression defines a set of prognostic biomarkers for lung cancer PLoS Med 7 2010 e1000378
28. R. Jimenez, M. Sanchez, M.J. Zarzuelo, M. Romero, A.M. Quintela, and R. Lopez-Sepulveda Endothelium-dependent vasodilator effects of peroxisome proliferator-activated receptor beta agonists via the phosphatidyl-inositol-3 kinase-Akt pathway J Pharmacol Exp Ther 332 2010 554 561
29. A. Kapoor, Y. Shintani, M. Collino, M.F. Osuchowski, D. Busch, and N.S. Patel Protective role of peroxisome proliferator-activated receptor-beta/delta in septic shock Am J Respir Crit Care Med 182 2010 1506 1515
30. D.J. Kim, M.T. Bility, A.N. Billin, T.M. Willson, F.J. Gonzalez, and J.M. Peters PPARbeta/delta selectively induces differentiation and inhibits cell proliferation Cell Death Differ 13 2006 53 60
31. D.J. Kim, K.S. Prabhu, F.J. Gonzalez, and J.M. Peters Inhibition of chemically induced skin carcinogenesis by sulindac is independent of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) Carcinogenesis 27 2006 1105 1112
32. T. Kino, K.C. Rice, and G.P. Chrousos The PPARdelta agonist GW501516 suppresses interleukin-6-mediated hepatocyte acute phase reaction via STAT3 inhibition Eur J Clin Invest 37 2007 425 433
33. S.A. Kliewer, B.M. Forman, B. Blumberg, E.S. Ong, U. Borgmeyer, and D.J. Mangelsdorf Differential expression and activation of a family of murine peroxisome proliferator-activated receptors Proc Natl Acad Sci U S A 91 1994 7355 7359
34. C.H. Lee, A. Chawla, N. Urbiztondo, D. Liao, W.A. Boisvert, and R.M. Evans Transcriptional repression of atherogenic inflammation: modulation by PPARdelta Science 302 2003 453 457
35. C.H. Lee, P. Olson, A. Hevener, I. Mehl, L.W. Chong, and J.M. Olefsky PPARdelta regulates glucose metabolism and insulin sensitivity Proc Natl Acad Sci U S A 103 2006 3444 3449
36. Y. Li, M. Connolly, C. Nagaraj, B. Tang, Z. Balint, and H. Popper Peroxisome proliferator-activated receptor-beta/delta, the acute signaling factor in prostacyclin-induced pulmonary vasodilation Am J Respir Cell Mol Biol 46 2012 372 379
37. S. Lieber, F. Scheer, W. Meissner, S. Naruhn, T. Adhikary, and S. Muller-Brusselbach (Z)-2-(2-bromophenyl)-3-{[4-(1-methyl-piperazine)amino] phenyl}acrylonitrile (DG172): an orally bioavailable PPARbeta/delta-selective ligand with inverse agonistic properties J Med Chem 55 2012 2858 2868
38. S. Luquet, J. Lopez-Soriano, D. Holst, A. Fredenrich, J. Melki, and M. Rassoulzadegan Peroxisome proliferator-activated receptor delta controls muscle development and oxidative capability FASEB J 17 2003 2299 2301
39. S. Mandard, and D. Patsouris Nuclear control of the inflammatory response in mammals by peroxisome proliferator-activated receptors PPAR Res 2013 2013 613864
40. H.E. Marin, M.A. Peraza, A.N. Billin, T.M. Willson, J.M. Ward, and M.J. Kennett Ligand activation of peroxisome proliferator-activated receptor beta inhibits colon carcinogenesis Cancer Res 66 2006 4394 4401
41. L. Michalik, J. Auwerx, J.P. Berger, V.K. Chatterjee, C.K. Glass, and F.J. Gonzalez International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors Pharmacol Rev 58 2006 726 741
42. T. Nagasawa, Y. Inada, S. Nakano, T. Tamura, T. Takahashi, and K. Maruyama Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet Eur J Pharmacol 536 2006 182 191
43. S.J. Newsholme, WSD, T. Brodie, C. Brennan, M. Brown, and L.E. Geiger Mouse carcinogenicity study with GW501516, a PPAR delta agonist Toxicologist 108 2009 896
44. K. Nishimura, N. Nakano, V.S. Chowdhury, M. Kaneto, M. Torii, and M.A. Hattori Effect of PPARbeta/delta agonist on the placentation and embryo-fetal development in rats Birth Defects Res B Dev Reprod Toxicol 98 2013 164 169
45. W.R. Oliver Jr., J.L. Shenk, M.R. Snaith, C.S. Russell, K.D. Plunket, and N.L. Bodkin A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport Proc Natl Acad Sci U S A 98 2001 5306 5311
46. E.J. Olson, G.L. Pearce, N.P. Jones, and D.L. Sprecher Lipid effects of peroxisome proliferator-activated receptor-delta agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome Arterioscler Thromb Vasc Biol 32 2012 2289 2294
47. E.M. Ooi, G.F. Watts, D.L. Sprecher, D.C. Chan, and P.H. Barrett Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity J Clin Endocrinol Metab 96 2011 E1568 E1576
48. J.M. Peters, J.E. Foreman, and F.J. Gonzalez Dissecting the role of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) in colon, breast, and lung carcinogenesis Cancer Metastasis Rev 30 2011 619 640
49. L. Piqueras, A.R. Reynolds, K.M. Hodivala-Dilke, A. Alfranca, J.M. Redondo, and T. Hatae Activation of PPARbeta/delta induces endothelial cell proliferation and angiogenesis Arterioscler Thromb Vasc Biol 27 2007 63 69
50. U. Riserus, D. Sprecher, T. Johnson, E. Olson, S. Hirschberg, and A. Liu Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men Diabetes 57 2008 332 339
51. C. Rohrl, U. Kaindl, I. Koneczny, X. Hudec, D.M. Baron, and J.S. Konig Peroxisome-proliferator-activated receptors gamma and beta/delta mediate vascular endothelial growth factor production in colorectal tumor cells J Cancer Res Clin Oncol 137 2011 29 39
52. B.G. Shearer, D.J. Steger, J.M. Way, T.B. Stanley, D.C. Lobe, and D.A. Grillot Identification and characterization of a selective peroxisome proliferator-activated receptor beta/delta (NR1C2) antagonist Mol Endocrinol 22 2008 523 529
53. B.G. Shearer, R.W. Wiethe, A. Ashe, A.N. Billin, J.M. Way, and T.B. Stanley Identification and characterization of 4-chloro-N-(2-{[5- trifluoromethyl)-2-pyridyl]sulfonyl}ethyl)benzamide (GSK3787), a selective and irreversible peroxisome proliferator-activated receptor delta (PPARdelta) antagonist J Med Chem 53 2010 1857 1861
54. L. Shen, Y. Zhang, A. Wang, E. Sieber-McMaster, X. Chen, and P. Pelton Synthesis and structure-activity relationships of thiadiazole-derivatives as potent and orally active peroxisome proliferator-activated receptors alpha/delta dual agonists Bioorg Med Chem 16 2008 3321 3341
55. D.L. Sprecher, C. Massien, G. Pearce, A.N. Billin, I. Perlstein, and T.M. Willson Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist Arterioscler Thromb Vasc Biol 27 2007 359 365
56. R.L. Stephen, M.C. Gustafsson, M. Jarvis, R. Tatoud, B.R. Marshall, and D. Knight Activation of peroxisome proliferator-activated receptor delta stimulates the proliferation of human breast and prostate cancer cell lines Cancer Res 64 2004 3162 3170
57. M.L. Sznaidman, C.D. Haffner, P.R. Maloney, A. Fivush, E. Chao, and D. Goreham Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta)-synthesis and biological activity Bioorg Med Chem Lett 13 2003 1517 1521
58. A. Tailleux, K. Wouters, and B. Staels Roles of PPARs in NAFLD: potential therapeutic targets Biochim Biophys Acta 1821 2012 809 818
59. I. Takada, R.T. Yu, H.E. Xu, M.H. Lambert, V.G. Montana, and S.A. Kliewer Alteration of a single amino acid in peroxisome proliferator-activated receptor-alpha (PPAR alpha) generates a PPAR delta phenotype Mol Endocrinol 14 2000 733 740
60. Y. Takata, J. Liu, F. Yin, A.R. Collins, C.J. Lyon, and C.H. Lee PPARdelta-mediated antiinflammatory mechanisms inhibit angiotensin II-accelerated atherosclerosis Proc Natl Acad Sci U S A 105 2008 4277 4282
61. J.D. Tugwood, I. Issemann, R.G. Anderson, K.R. Bundell, W.L. McPheat, and S. Green The mouse peroxisome proliferator activated receptor recognizes a response element in the 5' flanking sequence of the rat acyl CoA oxidase gene EMBO J 11 1992 433 439
62. J.M. Wallace, M. Schwarz, P. Coward, J. Houze, J.K. Sawyer, and K.L. Kelley Effects of peroxisome proliferator-activated receptor alpha/delta agonists on HDL-cholesterol in vervet monkeys J Lipid Res 46 2005 1009 1016
63. J. Youssef, and M. Badr Peroxisome proliferator-activated receptors and cancer: challenges and opportunities Br J Pharmacol 164 2011 68 82
64. R.Y. Yu, X. Wang, F.J. Pixley, J.J. Yu, A.L. Dent, and H.E. Broxmeyer BCL-6 negatively regulates macrophage proliferation by suppressing autocrine IL-6 production Blood 105 2005 1777 1784
65. L. Zeng, Y. Geng, M. Tretiakova, X. Yu, P. Sicinski, and T.G. Kroll Peroxisome proliferator-activated receptor-delta induces cell proliferation by a cyclin E1-dependent mechanism and is up-regulated in thyroid tumors Cancer Res 68 2008 6578 6586
66. R. Zhang, A. Deangelis, A. Wang, E. Sieber-McMaster, X. Li, and R. Russell Discovery and SAR of para-alkylthiophenoxyacetic acids as potent and selective PPARdelta agonists Bioorg Med Chem Lett. 19 2009 1101 1104